CanSino Biologics' PCV13i vaccine receives China approval

CanSino Biologics Inc. has received approval from China's National Medical Products Administration (NMPA) for its new drug application (NDA) for the PCV13i vaccine. The PCV13i targets infants and young children under two years old and uses a dual vector technology to reduce immunosuppression during co-injection with other vaccines, as well as a animal-free fermentation medium to reduce risk and traditional phenol purification processing. The company believes this approval lays a foundation for developing higher-valent pneumococcal conjugate vaccines, with a similar market positioning to its current Menhycia® vaccine. It aims to enrich the company's product portfolio and enhance its marketing efficiency.